Daiichi Life Insurance Co. Ltd. Invests $28.58 Million in AbbVie Inc. $ABBV

Key Points

• Daiichi Life Insurance acquired 113,568 AbbVie shares worth approximately $28.58 million during the second quarter. Institutional investors collectively own 70.23% of AbbVie’s outstanding stock.
• AbbVie exceeded quarterly expectations, reporting $3.65 in adjusted earnings per share and $16.99 billion in revenue, with revenue up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analysts maintain a generally positive view, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $275.95 versus its reported share price of $261.50. The company also pays a quarterly dividend of $1.73 per share, yielding approximately 2.6%.

Daiichi Life Insurance Co. Ltd. bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 113,568 shares of the company's stock, valued at approximately $28,578,000.

A number of other institutional investors have also recently bought and sold shares of ABBV. Norges Bank acquired a new position in shares of AbbVie in the 4th quarter valued at $5,865,055,000. Wellington Management Group LLP grew its stake in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the period. Capital World Investors increased its holdings in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company's stock worth $2,986,777,000 after buying an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. increased its holdings in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock worth $1,244,112,000 after buying an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after buying an additional 4,190,487 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company's stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $261.50 on Thursday. The company has a market cap of $462.02 billion, a P/E ratio of 73.87, a PEG ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The business's 50-day simple moving average is $254.23 and its 200 day simple moving average is $229.67.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is presently 195.48%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ABBV shares. UBS Group lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Canaccord Genuity Group raised their price objective on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Piper Sandler lifted their price objective on AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Finally, Guggenheim boosted their target price on AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source